Neuropsychiatric adverse drug reactions associated with low dose methotrexate in rheumatoid arthritis patients.
Jette A van LintTom BakkerPeter M Ten KloosterEugene P van PuijenbroekHarald E VonkemanNaomi T JessurunPublished in: Expert opinion on drug safety (2021)
Knowledge on the nature, frequency and impact of the demonstrated NPADRs during LDMTX therapy will enhance attention toward these potential ADRs allowing better risk assessment and communication to patients.
Keyphrases
- adverse drug
- rheumatoid arthritis patients
- low dose
- risk assessment
- end stage renal disease
- high dose
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- prognostic factors
- electronic health record
- emergency department
- patient reported outcomes
- heavy metals
- systemic lupus erythematosus
- mesenchymal stem cells
- climate change
- replacement therapy